HC Wainwright Forecasts Strong Price Appreciation for TriSalus Life Sciences (NASDAQ:TLSI) Stock

TriSalus Life Sciences (NASDAQ:TLSI) had its price objective increased by equities researchers at HC Wainwright from $11.00 to $12.00 in a research note issued on Wednesday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 143.41% from the company’s current price.

A number of other equities analysts have also recently issued reports on the company. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Zacks Research raised shares of TriSalus Life Sciences to a “hold” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.00.

TriSalus Life Sciences Price Performance

TLSI opened at $4.93 on Wednesday. The company has a fifty day moving average price of $4.88 and a two-hundred day moving average price of $4.31. The firm has a market capitalization of $303.59 million, a PE ratio of -3.79 and a beta of 0.44. TriSalus Life Sciences has a 52 week low of $2.20 and a 52 week high of $7.95. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). The company had revenue of $11.41 million for the quarter, compared to analyst estimates of $10.27 million. As a group, analysts anticipate that TriSalus Life Sciences will post -0.31 earnings per share for the current year.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently modified their holdings of TLSI. Bank of America Corp DE boosted its position in shares of TriSalus Life Sciences by 1.9% during the first quarter. Bank of America Corp DE now owns 201,719 shares of the company’s stock worth $807,000 after buying an additional 3,703 shares during the period. Cura Wealth Advisors LLC acquired a new stake in TriSalus Life Sciences in the 2nd quarter valued at approximately $36,000. Renaissance Technologies LLC acquired a new stake in TriSalus Life Sciences in the 1st quarter valued at approximately $124,000. Deutsche Bank AG bought a new stake in TriSalus Life Sciences in the 2nd quarter valued at approximately $221,000. Finally, Corient Private Wealth LP boosted its position in TriSalus Life Sciences by 61.7% during the 2nd quarter. Corient Private Wealth LP now owns 147,152 shares of the company’s stock worth $670,000 after acquiring an additional 56,152 shares during the last quarter. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company’s approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration.

TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure.